Published in NMR Biomed on January 28, 2011
Molecular imaging of the tumor microenvironment for precision medicine and theranostics. Adv Cancer Res (2014) 0.85
MR - eyes for cancer: looking within an impenetrable disease. NMR Biomed (2013) 0.79
Dynamic (18) F-FDG PET for Assessment of Tumor Physiology in Two Breast Carcinoma Xenografts. Nucl Med Mol Imaging (2013) 0.75
Imaging the Tumor Microenvironment. Cancer J (2015) 0.75
Theranostic imaging of cancer. Eur J Radiol (2012) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 17.64
Nonlinear magic: multiphoton microscopy in the biosciences. Nat Biotechnol (2003) 13.29
Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res (1989) 12.85
The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer (1955) 10.49
Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 8.86
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene (2009) 8.01
Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed (2004) 6.94
The impact of O2 availability on human cancer. Nat Rev Cancer (2008) 6.84
Arachidonic acid metabolism. Annu Rev Biochem (1986) 6.56
Lymphangiogenesis: Molecular mechanisms and future promise. Cell (2010) 5.84
Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol (2005) 5.80
Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med (2003) 5.50
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther (2006) 4.20
Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med (1998) 3.85
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res (2009) 3.40
Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med (2010) 3.10
Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res (2006) 3.05
Cancer related inflammation: the macrophage connection. Cancer Lett (2008) 2.88
Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr Opin Genet Dev (2009) 2.85
Immune cells as mediators of solid tumor metastasis. Cancer Metastasis Rev (2008) 2.85
Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen (2009) 2.83
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood (2007) 2.74
Are cancer cells acidic? Br J Cancer (1991) 2.72
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res (2003) 2.66
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res (2009) 2.62
Tumour vascular targeting. Nat Rev Cancer (2005) 2.56
Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res (2006) 2.35
PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials (2010) 2.31
Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A (2003) 2.23
MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J (2005) 2.03
Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res (2007) 2.03
Chemokines in hematopoiesis. Curr Opin Hematol (2008) 2.01
Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res (2007) 2.01
18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. Nucl Med Biol (2004) 1.99
The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology (2005) 1.83
Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? J Bioenerg Biomembr (2007) 1.83
Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A (2009) 1.81
Expression of Tie-2 by human monocytes and their responses to angiopoietin-2. J Immunol (2007) 1.79
Cellular and molecular pathways linking inflammation and cancer. Immunobiology (2009) 1.78
Synergistic effects of light-emitting probes and peptides for targeting and monitoring integrin expression. Proc Natl Acad Sci U S A (2005) 1.72
Targeting the tumor microenvironment. Front Biosci (2007) 1.72
Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials (2008) 1.70
Tie2-expressing monocytes and tumor angiogenesis: regulation by hypoxia and angiopoietin-2. Cancer Res (2007) 1.70
Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res (2010) 1.66
Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small (2009) 1.64
HIF-1 inhibitors for cancer therapy: from gene expression to drug discovery. Curr Pharm Des (2009) 1.59
Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol (2003) 1.57
Involvement of extracellular matrix constituents in breast cancer. Semin Cancer Biol (1995) 1.57
Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia (2005) 1.54
COX-2 inhibition and colorectal cancer. Semin Oncol (2004) 1.53
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
Protons make tumor cells move like clockwork. Pflugers Arch (2009) 1.48
Human lupus T cells resist inactivation and escape death by upregulating COX-2. Nat Med (2004) 1.47
Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res (2010) 1.44
Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer (2007) 1.42
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
The cyclooxygenase reaction mechanism. Biochemistry (2002) 1.38
Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol (2003) 1.38
The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat (2007) 1.38
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res (2007) 1.30
Nanoparticle-induced vascular blockade in human prostate cancer. Blood (2010) 1.30
Macrophage imaging in central nervous system and in carotid atherosclerotic plaque using ultrasmall superparamagnetic iron oxide in magnetic resonance imaging. Invest Radiol (2004) 1.26
In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol (2006) 1.26
Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol (2008) 1.23
Optical imaging of spontaneous breast tumors using protease sensing 'smart' optical probes. Invest Radiol (2005) 1.22
Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol (2005) 1.20
Advances in eicosanoid research, novel therapeutic implications. Biochem Biophys Res Commun (2010) 1.16
Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res (2005) 1.15
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Behavior of immune players in the tumor microenvironment. Curr Opin Oncol (2009) 1.11
Matrix metalloproteinase dependent and independent collagen degradation. Front Biosci (2006) 1.09
Developmental and pathological lymphangiogenesis: from models to human disease. Histochem Cell Biol (2008) 1.07
Magnetic resonance visualization of tumor angiogenesis by targeting neural cell adhesion molecules with the highly sensitive gadolinium-loaded apoferritin probe. Cancer Res (2006) 1.07
Changes in blood perfusion and hypoxia after irradiation of a human squamous cell carcinoma xenograft tumor line. Radiat Res (2000) 1.06
Emerging therapeutic targets in breast cancer bone metastasis. Future Oncol (2010) 1.06
Effect of antisense hypoxia-inducible factor 1alpha on progression, metastasis, and chemosensitivity of pancreatic cancer. Pancreas (2006) 1.06
The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem (2006) 1.04
Bovine serum albumin-based magnetic nanocarrier for MRI diagnosis and hyperthermic therapy: a potential theranostic approach against cancer. Small (2010) 1.03
Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. Mol Pharm (2010) 1.03
Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res (1995) 1.03
Cyclooxygenase-2 enhances alpha2beta1 integrin expression and cell migration via EP1 dependent signaling pathway in human chondrosarcoma cells. Mol Cancer (2010) 1.02
Hypoxia, angiogenesis and cancer therapy: to breathe or not to breathe? Cell Cycle (2009) 1.01
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Development of pH-responsive chitosan/heparin nanoparticles for stomach-specific anti-Helicobacter pylori therapy. Biomaterials (2009) 1.00
Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res (2006) 1.00
Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem (2006) 0.99
A molecularly targeted theranostic probe for ovarian cancer. Mol Cancer Ther (2010) 0.98
Hyperpolarized (13)C magnetic resonance detection of carboxypeptidase G2 activity. Magn Reson Med (2009) 0.98
In vivo tumor diagnosis and photodynamic therapy via tumoral pH-responsive polymeric micelles. Chem Commun (Camb) (2010) 0.98
EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway. Mol Pharmacol (2010) 0.97
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
MRI of the tumor microenvironment. J Magn Reson Imaging (2002) 2.87
Choline metabolism in malignant transformation. Nat Rev Cancer (2011) 2.85
Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res (2004) 2.43
Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem (2003) 2.12
Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res (2003) 2.05
Natural D-glucose as a biodegradable MRI contrast agent for detecting cancer. Magn Reson Med (2012) 1.84
RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res (2005) 1.77
MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn Reson Med (2003) 1.76
Extracellular acidification alters lysosomal trafficking in human breast cancer cells. Neoplasia (2004) 1.70
Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res (2010) 1.65
Choline metabolism in cancer: implications for diagnosis and therapy. Expert Rev Mol Diagn (2006) 1.54
Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res (2008) 1.52
Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res (2006) 1.41
Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm (2006) 1.37
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Self-assembled three dimensional radio frequency (RF) shielded containers for cell encapsulation. Biomed Microdevices (2005) 1.28
Choline kinase down-regulation increases the effect of 5-fluorouracil in breast cancer cells. Cancer Res (2007) 1.27
Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res (2009) 1.27
Hypoxia regulates CD44 and its variant isoforms through HIF-1α in triple negative breast cancer. PLoS One (2012) 1.25
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
Metabolic tumor imaging using magnetic resonance spectroscopy. Semin Oncol (2011) 1.22
Metabolomics of cancer. Methods Mol Biol (2009) 1.21
Magnetic resonance imaging of cell surface receptors using targeted contrast agents. Curr Pharm Biotechnol (2004) 1.17
Characterizing extravascular fluid transport of macromolecules in the tumor interstitium by magnetic resonance imaging. Cancer Res (2005) 1.15
Silencing of cyclooxygenase-2 inhibits metastasis and delays tumor onset of poorly differentiated metastatic breast cancer cells. Mol Cancer Res (2007) 1.14
PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med (2008) 1.13
Vanin-1(-/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest (2004) 1.13
Hypoxic tumor microenvironments reduce collagen I fiber density. Neoplasia (2010) 1.12
Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia (2009) 1.10
Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging (2005) 1.08
Collagen I fiber density increases in lymph node positive breast cancers: pilot study. J Biomed Opt (2012) 1.08
Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.06
Multimodal mass spectrometric imaging of small molecules reveals distinct spatio-molecular signatures in differentially metastatic breast tumor models. Cancer Res (2010) 1.06
Mass spectrometry images acylcarnitines, phosphatidylcholines, and sphingomyelin in MDA-MB-231 breast tumor models. J Lipid Res (2012) 1.04
Choline kinase overexpression increases invasiveness and drug resistance of human breast cancer cells. NMR Biomed (2010) 1.03
Toward digital staining using imaging mass spectrometry and random forests. J Proteome Res (2009) 1.02
Anti-inflammatory agent indomethacin reduces invasion and alters metabolism in a human breast cancer cell line. Neoplasia (2007) 1.02
Molecular Imaging of Cancer: Applications of Magnetic Resonance Methods. Proc IEEE Inst Electr Electron Eng (2005) 1.02
Image-guided enzyme/prodrug cancer therapy. Clin Cancer Res (2008) 1.01
Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano (2010) 1.01
Molecular-functional imaging of cancer: to image and imagine. Trends Mol Med (2007) 1.00
Hypoxia increases breast cancer cell-induced lymphatic endothelial cell migration. Neoplasia (2008) 1.00
Lymph node metastasis in breast cancer xenografts is associated with increased regions of extravascular drain, lymphatic vessel area, and invasive phenotype. Cancer Res (2006) 1.00
Molecular and functional imaging of cancer: advances in MRI and MRS. Methods Enzymol (2004) 1.00
Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol (2007) 0.99
Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR Biomed (2012) 0.99
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol (2010) 0.98
Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia (2006) 0.97
Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn Reson Med (2002) 0.96
Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther (2007) 0.95
Concise representation of mass spectrometry images by probabilistic latent semantic analysis. Anal Chem (2008) 0.95
Multimodal image-guided enzyme/prodrug cancer therapy. J Am Chem Soc (2006) 0.95
Multiscale imaging and computational modeling of blood flow in the tumor vasculature. Ann Biomed Eng (2012) 0.94
Pharmacodynamic markers for choline kinase down-regulation in breast cancer cells. Neoplasia (2009) 0.94
Proline oxidase promotes tumor cell survival in hypoxic tumor microenvironments. Cancer Res (2012) 0.94
Fiducial markers for combined 3-dimensional mass spectrometric and optical tissue imaging. Anal Chem (2012) 0.94
Inflammation, but not hypoxia, mediated HIF-1alpha activation depends on COX-2. Cancer Biol Ther (2009) 0.94
Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol Imaging (2008) 0.94
Localized hypoxia results in spatially heterogeneous metabolic signatures in breast tumor models. Neoplasia (2012) 0.93
Loss of p53 function in colon cancer cells results in increased phosphocholine and total choline. Mol Imaging (2004) 0.93
Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat (2004) 0.92
Applications of molecular MRI and optical imaging in cancer. Future Med Chem (2010) 0.92
Hypoxia and the presence of human vascular endothelial cells affect prostate cancer cell invasion and metabolism. Neoplasia (2007) 0.92
Cell viability and noninvasive in vivo MRI tracking of 3D cell encapsulating self-assembled microcontainers. Cell Transplant (2007) 0.91
MR molecular imaging of tumor vasculature and vascular targets. Adv Genet (2010) 0.91
Magnetic resonance imaging and spectroscopy of transgenic models of cancer. NMR Biomed (2007) 0.90
Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft. Cancer Res (2009) 0.90
Single- and multiple-dose pharmacokinetics of exendin-4 in rhesus monkeys. Int J Pharm (2007) 0.90
COX-2 in cancer: Gordian knot or Achilles heel? Front Pharmacol (2013) 0.89
Synthesis of 6'-O-lissamine-rhodamine B-glucosamine as a novel probe for fluorescence imaging of lysosomes in breast tumors. Bioconjug Chem (2005) 0.89
An alternative paper based tissue washing method for mass spectrometry imaging: localized washing and fragile tissue analysis. J Am Soc Mass Spectrom (2011) 0.88